We compared inpatient and outpatient costs alongside clinical outcomes associated with hematopoietic cell transplantation between 2000 and 2003 with high-dose regimens (HDCT, n ¼ 185) and with reduced intensity regimens (RICT, n ¼ 90) from human leukocyte antigen (HLA)-matched donors for patients with hematological malignancies. With a comparable median follow-up of 3 years, long-term clinical outcomes, including cumulative incidence of chronic graft-vs-host disease, disease-free survival and overall survival, were similar between the two groups. In the univariate analysis, median costs for the first 100 days ($104 380 vs $42 149) and 1 year ($128 253 vs $80 499) in the HDCT group were higher than those in the RICT group. Median days of hospitalization are also higher for HDCT recipients (39 vs 21), although the number of outpatient clinic visits for HDCT recipients were fewer compared to that for RICT recipients (16 vs 25) during the first year. Adjusting for patient characteristics, RICT recipients had approximately 16 fewer days of hospitalization and cost $53 030 less than HDCT recipients within the first year after transplantation. Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of longterm clinical outcomes compared to HDCT procedures.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning regimens (RICT) has been explored as a treatment for patients with hematological diseases who are ineligible to receive HCT with high-dose conditioning regimens (HDCT) because of older age or comorbidities. [1] [2] [3] [4] [5] The published literature suggests that RICT may have several advantages compared with HDCT. In some studies, the frequencies of severe transplant-related toxicities, including veno-occlusive disease (VOD), pulmonary opportunistic infections and other pulmonary complications such as idiopathic pneumonia syndrome, diffuse alveolar hemorrhage and bronchiolitis obliterans, are less in RICT recipients than in HDCT recipients. [6] [7] [8] [9] [10] [11] In addition, recovery of neutrophil and platelet counts were faster in RICT recipients, resulting in decreased transfusion requirements and antibiotic use. [12] [13] [14] [15] [16] Many patients receiving RICTs may be treated entirely as outpatients or may need fewer hospitalization days compared with patients receiving HDCTs. 9, 13 Although RICT recipients receive less toxic dosages of chemotherapy and/or radiation, they are still at risk of developing some serious complications after transplantation, including graft-vs-host disease (GvHD). The incidence of acute GvHD and chronic GvHD with RICT is variable in the literature depending on the specific patient populations, GvHD prophylaxis, HLA matching and other factors. 11 In addition, some previous reports indicated that the median onset of acute GvHD was later in RICT recipients, resulting in an important risk factor for viral infections. 9, [17] [18] [19] In aggregate, these findings suggest that RICT recipients may have lower costs soon after HCT while, in the later phase, the risk of complications and relapse may result in higher costs than in HDCT recipients. In addition, several observational studies have suggested comparative clinical outcomes between HDCT and RICT. 18, [20] [21] [22] It is premature to conclude which procedure is clinically superior at this point, given the different baseline patient characteristics or specific disease circumstances. However, if similar clinical outcomes can be achieved, it would be better for society to use the lowercost procedure. Although randomized trials offer the best comparison between two treatment options, observational data with enough sample size, which are associated with financial, practical and ethical advantages, offer the best data in a practical setting in the meantime. Thus, we compared total (inpatient and outpatient) costs associated with HDCT and RICT approaches during the first year after HCT.
Patients and methods

Patient population
The potentially eligible study population included 457 consecutive patients undergoing HCT for hematological diseases from June 2000 through September 2003. Ten patients among these 457 patients were excluded because they had received prior HCT within a year of the index transplantation procedure. One hundred seventy-two patients, who received T-cell-depleted (62 HDCTs, 3 RICTs), HLA-mismatched (44 HDCTs, 8 RICTs) or cord blood grafts (1 HDCT) and/or who had other diseases (chronic lymphocytic leukemia, Hodgkin's disease and multiple myeloma, other leukemia or benign hematological diseases -17 HDCTs, 53 RICTs) were excluded from this study to improve the comparability of the two procedures. Thus, the final study population included 275 patients undergoing HLA-matched HCT for hematological malignancies at the Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA (DFCI/BWH). Approval was obtained from the institutional review board at the DFCI/ BWH for these studies. Written informed consent for transplantation was provided by patients according to the Declaration of Helsinki.
Disease status was categorized before transplantation into two groups. Less advanced diseases were defined as acute myeloid leukemia or acute lymphoblastic leukemia (ALL) in first remission, chronic myeloid leukemia in chronic phase, lymphoma in first remission and refractory anemia without excess blasts. All other stages and types of hematological malignancies were considered as advanced disease.
Intensity of conditioning (RICT vs HDCT), GvHD prophylaxis and/or graft source were protocol driven or based on attending physician recommendation and patient preferences after a discussion of the risks and benefits of each method. Patients were treated on a variety of clinical protocols. The day of graft infusion was designated day 0. HLA matching was performed using both serologic and molecular methods. Our transplant program employs a primary outpatient physician model so that all pretransplantation and post-transplantation care is delivered by the same physician. Although the composition of individual practices varied, all physicians cared for both HDCT and RICT recipients. It is our usual practice to admit RICT recipients only for the delivery of chemotherapy and graft infusion, discharging them on day þ 1 in the absence of transplant-related complications. In contrast, HDCT recipients remain hospitalized for conditioning and throughout their neutropenia and post-transplant recovery period. Outpatients were usually followed equally in both groups with the interval period of a few days soon after hospital discharge, then followed by the interval period of between a week and 2 weeks through 100 days, and thereafter followed by the interval period of between 2 weeks and 1 month through 1 year after transplantation when clinically feasible. In our study, the median interval period between regular clinic visits in each group, which was calculated by dividing total follow-up days as an outpatient by the total number of clinic visits within a year after transplantation, was different between the two groups: once every 31 days for the HDCT group and once every 18 days for the RICT group (P ¼ 0.01). Most patients were followed at the DFCI/BWH through the first year post-transplantation as described in the data collection of cost data. If readmission is necessary, they are usually readmitted to the DFCI/BWH or transferred there shortly after readmission at their local hospitals.
Data collection
Cost data, days of hospitalization and the number of outpatient clinic visits. All inpatient cost information, with dates of admission before day 0 (but that include day 0) to 365 days after their transplantations and all outpatient costs within a year of post-transplantation, were retrieved from the institutional accounting system (regardless of date of discharge). Because of the retrospective nature of this analysis and the limitations of available accounting systems, it was not possible to collect costs of prescriptions and inpatient and outpatient costs accrued outside the DFCI/BWH's system. To address concerns about underestimating total costs due to missing data, we conducted a chart review for all the patients and contacted local physicians to identify clinic visits and rehospitalizations outside of the DFCI/BWH's system. Twenty-three of 185 HDCT recipients (12%) and also 11 of 90 RICT recipients (12%) were seen for at least one clinic visit outside of DFCI/BWH at a median of 1 month (range 0-10 months) in the HDCT group and 1 month (range 0-8 months) in the RICT group. However, all these patients also continued to be seen at DFCI/BWH through 1 year post-transplant or until their deaths; visits to outside clinics accounted for 2% of total clinic visits at DFCI/BWH in both groups. Prolonged hospitalization at outside institutions was likewise rare. Ten of 185 HDCT recipients (data not available for 1) and 3 of 90 RICT recipients (data not available for 2) were hospitalized outside of the DFCI/BWH system within the first year. These hospitalizations at outside institutions, in comparison to those at DFCI/BWH accounted for 279 of 8362 days (3.3%) in the HDCT and 42 of 2895 days (1.5%) in the RICT group. These findings suggest that costs accrued outside of the DFCI/BWH accounting system occurred equally in both groups and accounted for a negligible fraction of the total cost collected in this study.
We also excluded nonmedical costs 23 such as caregiver time, transportation and local housing costs, because these are expected to be equal in both groups and low compared with direct medical costs as previously noted. In addition, we excluded costs of identifying and obtaining graft source from unrelated donors since we did not have access to comparable costs for related donor recipients.
Outpatient and inpatient costs were estimated using a relative value units (RVUs) methodology, 24 where costs were calculated by applying unit costs assigned to each medical service item to each patient's resource utilization, and were adjusted for inflation to the year 2004 (US dollars), using the medical care component of the consumer price index.
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Days of hospitalization, with dates of admission to 1 year post-transplant and the number of outpatient clinic visits through 1 year post-transplant, were also obtained to interpret cost data.
Cost exclusion
We reviewed all cases in which patients were admitted 10 or more days before day 0, but remained hospitalized continuously through day 0 to identify costs not attributable to HCT. Fifteen patients (nine HDCTs, six RICTs) were admitted from day À10 to less than 1 month (admitted À10, À10, À12, À12, À13, À14, À15, À16 and À19 days in HDCT group, and admitted À10, À10, À11, À13, À22 and À29 days in RICT group) for the following reasons: treatment for complications of underlying disease, such as pain control, transfusion and bleeding (n ¼ 3), and fever caused by underlying disease or chemotherapy (n ¼ 12). These patients were scheduled to receive HCT after control of these issues, and thus these costs were felt to be directly related to the preparation for HCT and were included in the analysis.
Two patients were admitted more than 1 month before transplantation, who remained continuously as inpatients until their transplantations. One HDCT recipient was admitted 34 days before transplantation for treatment of the underlying disease with a plan to proceed directly to HCT. These costs were included. One RICT recipient was admitted 114 days before transplantation. Review of this case showed admission for induction chemotherapy, and he/she only proceeded to transplantation because prior therapy failed, so we excluded this patient in the cost analysis to compare the costs and days of hospitalization on a fair and equitable basis. In sensitivity analyses, we confirmed that cost exclusion of this one RICT recipient did not change the result.
There were seven patients who received two or more transplants within a year in the following combinations: RICT-RICT (n ¼ 1), RICT-HDCT (n ¼ 3), HDCT-RICT (n ¼ 1) and RICT-RICT-HDCT (n ¼ 2). For analysis, patients were categorized according to their first transplant conditioning regimen (one HDCT, six RICTs). In these cases, the costs of their second and third HCTs were included because they occurred within a year from the index transplantation (since the costs for subsequent transplants were thought to reflect failure of the first transplantation). However, in sensitivity analyses, we tested the effect of excluding any second or third transplant procedure costs.
Clinical data
Clinical information on survival, relapse, and acute and chronic GvHD was obtained from the clinical transplant database and patients' records. Relapse was diagnosed based on hematologic parameters, tissue biopsy, bone marrow (BM) biopsy findings and cytogenetic or molecular methods, according to particular disease presentations. The consensus conference was used for grading of acute GvHD, 26 and chronic GvHD was graded according to published criteria. 27 All analyses were performed on data collected through January 2006.
Biostatistical analysis
Heterogeneity of costs and days of hospitalization between the two groups was compared by analysis of variance (ANOVA), adjusted for seven key factors. The key factors included patient age (more than 50 years vs less than or equal to 50 years), donor age (more than 50 years vs less than or equal to 50 years), patient-donor sex matching (female donor and male patient vs all other combinations), patient-donor relationship (unrelated vs related), patientdonor CMV serological status (CMV-positive serology in either donor or patient vs CMV-negative serology both in patient and donor), disease status (advanced vs less advanced) and graft source (BM vs peripheral blood (PB)). For tests of heterogeneity, we used the natural logarithm of the cost and days of hospitalization data, because this transformation approximated a normal distribution and was effective in stabilizing the variances. However, all estimates and confidence intervals (CIs) presented have been transformed back to the original scales (dollars and days) and thus correspond to ratios. We explored all the ANOVA models that included intensity of conditioning, one of the seven possible factors and the two-way interaction between the factor and the intensity of conditioning. Our goal was to ascertain if there were factors for which the magnitude of the effect of the intensity of conditioning differed according to the level of the factor. For any significant interaction effects (Po0.05), we estimated the intensity of conditioning effect separately for each level of the factor. We report and examine ratios of cost and days of hospitalization and the respective 95% CIs for each level of the factor.
Disease-free survival (DFS) was defined as the length of time from the date of transplant to any recurrent disease or death, whichever occurred first. Overall survival (OS) was defined as the length of time from the date of transplant to death from any cause. DFS and OS percentages, standard errors and intensity of conditioning effect comparisons were obtained from the Kaplan-Meier method, 28 Greenwood's formula 29 and log-rank tests, 30 respectively. Cox proportional hazards regression models 31 were used to estimate relative risks and 95% CIs for the intensity of conditioning comparisons unadjusted and adjusted for the seven key factors. Since multiple Cox regression analysis uses a model in which all factors are considered as covariates, it may not be suitable when data include factors that confound both the treatment decision and its outcomes. To overcome this issue, we applied the propensity score (PS) in sensitivity analysis, which was introduced by Rosenbaum and Rubin in 1983. 32 We calculated the PS from the perspective of the probability of receiving RICT with a logistic regression model in which the outcome variable plays no role. Multiple Cox regression adjustment with individual PS was obtained to estimate survival. This statistical tool allowed us to compare the clinical effects of two treatment groups with the situation in which confounding factors are substantially reduced. A subgroup analysis of patients over 50 years was also examined to address concerns about the patient selection bias based on the idea that older patients were more likely to receive RICT procedure. Cumulative incidence of acute or chronic GvHD is reported separately with subsequent transplant and death as competing risks. 33 Results are reported at a median follow-up of 3 years.
To investigate the external validity, that is the generalizability of the results, we performed a sensitivity analysis comparing costs and clinical outcomes with the complete data set of all 447 patients receiving allogeneic transplant procedures during the study period.
Associations between categorical variables and intensity of conditioning (HDCT vs RICT) were assessed by a Fisher's exact test. 34 The Wilcoxon's rank-sum test was used for testing differences between continuous variables. 35 No statistical adjustment was made for performing multiple tests, but a P-value of more than 0.01 should be interpreted with care. P-values are two-sided tests.
Results
Patient and transplantation characteristics
Patient and transplantation characteristics are summarized in Table 1 ; 185 patients (67%) received HDCT and 90 patients (33%) received RICT. The groups were similar in donor age, patient-donor sex matching, patient-donor relationship, CMV serological status, blood type and year of transplant. Although the spectrum of diseases differed slightly between the two groups with a higher proportion of ALL in the HDCT group, they were similar in disease risk. However, the RICT group was more likely to have patients with older age and PB grafts than the HDCT group. All the RICT patients received a fludarabine-(30 mg/m 2 /day Â 4 days) and busulfan-(0.8 mg/kg/day Â 4 days) based conditioning regimen, and about 60% received GvHD prophylaxis with a calcineurin inhibitor (cyclosporine or tacrolimus)-based regimen with or without prednisolone. In the HDCT group, most patients received cyclophosphamide and total body irradiation-based conditioning and also received GvHD prophylaxis with calcineurin inhibitorbased regimens with or without sirolimus and/or methotrexate.
The primary indication for patients receiving RICT was patients' age over 50 years (n ¼ 37, 41%), prior autologous or allogeneic HDCT (n ¼ 17, 19%), disease type (n ¼ 22, 24%) and other medical condition/organ dysfunction (n ¼ 14, 16%). Data were not available to calculate recently published comorbidity scores. 36, 37 Costs, days of hospitalization and the number of outpatient clinic visits Days of hospitalization and costs within the first year were positively correlated (r ¼ 0.90, Po0.01) as expected. Outpatient costs were 16% of total costs within the first year after transplantation and higher in the RICT group than in the HDCT group (28 vs 11%, Po0.01). Univariate comparisons are shown in , Po0.01 for 1 year) during the first year after transplantation. Costs for the first 100 days after transplantation accounted for 81% of total costs during the first year in the HDCT group, as against 52% in the RICT group. Cost divided by the survival days after transplantation was also higher in HDCT recipients (median (IQR): $249/day (110-1198) vs $169/day (75-710), Po0.01). In contrast, the number of outpatient clinic visits was higher in RICT recipients during the first year (median (IQR): 9 (5-12) vs 14 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) for 100 days, Po0.01; 16 (7-29) vs 25 (13-38) for 1 year).
Results from the separate ANOVA analyses are presented in Table 3 . Our data show that, after controlling for key factors, costs were on average 70% higher for HDCT than RICT recipients ($129 483 vs $76 453, ratio 1.7, 95% CI 1.4-2.1, Po0.01). Costs for patients with unrelated donors were also significantly higher than costs for patients with related donors ($116 819 vs $84 741, ratio 1.4, 95% CI 1.2-1.6, Po0.01), controlling for all other variables including intensity of conditioning (HDCT vs RICT). There was a trend for patients with advanced disease to be more costly than those with less advanced disease ($108 594 vs $91 160, ratio 1.2, 95% CI 1.0-1.4, P ¼ 0.04). We included year of transplantation in the model to explore the possible association between the transplanted years to costs. Costs varied significantly by year of transplantation, but these changes were not in linear fashion.
We explored whether consideration of early engraftment, defined as no neutrophil nadir or engraftment within 10 days after stem cell infusion and acute GvHD (yes vs no), could explain our results. When these variables were included in the model, an association between HDCT and RICT on overall costs was still detectable (HDCT vs RICT: $123 506 vs $82 820, ratio 1.5, 95% CI 1.2-1.9, Po0.01).
Adjusting for all other patient characteristics, days of hospitalization was also longer for HDCT recipients (38 vs 22 days, ratio 1.8, 95% CI 1.4-2.1, Po0.01).
Thus, RICT procedures cost approximately $53 030 less and are associated with 16 fewer days of hospitalization than HDCT procedures within the first year after transplantation, adjusting for all other patient characteristics.
Several sensitivity analyses were performed to test the robustness of our conclusions. The estimated propensity to receive RICT ranged from 0.04 to 0.90 for RICT recipients and from 0.01 to 0.90 for HDCT recipients. Inclusion of PS in the multivariate analysis of costs and days of hospitalization produced the same results, suggesting that type of transplant procedure is independently associated with cost outcomes (costs for HDCT vs RICT: $128 438 vs $74 336, ratio 1.7, 95% CI 1.4-2.2, Po0.01; days of hospitalization for HDCT vs RICT: 38 vs 22 days, ratio 1.8, 95% CI 1.4-2.1, Po0.01). When excluding patients of less than 50 years, there were 34 HDCT recipients and 70 RICT recipients. A subgroup analysis of patients over 50 years did not change our results. In addition, 172 patients were excluded from the primary analysis because of T-cell depletion, HLA-mismatching, cord blood grafts or less common diagnoses. Inclusion of these patients also did not change conclusion. There were seven patients who received more than one transplant procedure during the study period. Exclusion of costs for these subsequent transplantations, likewise, did not change any conclusions. Table 4 summarizes unadjusted clinical outcomes. Fortynine percent of patients receiving RICTs did not experience a neutrophil nadir and the remaining patients who did a Less advanced diseases were defined as AML or ALL in first remission, CML in a chronic phase, lymphoma in first remission and refractory anemia without excess blasts. All other stages and types of hematological malignancies were considered advanced disease.
Clinical outcomes
experience nadir had significantly faster neutrophil recovery. The median time to a neutrophil count of at least 0.5 Â 10 9 /l was 12 days for RICT recipients who experienced nadir and 16 days for the HDCT recipients (Po0.01). In terms of platelet recovery, 47% of RICT recipients did not experience nadir, and the median time to platelet count of at least 20 Â 10 9 /l was 20 days for RICT recipients who experienced nadir and 23 days for the HDCT recipients (P ¼ 0.09).
The cumulative incidence of acute GvHD by 100 days was sooner and higher in patients receiving HDCTs (52 vs 34%, Po0.01). The cumulative incidence of any chronic GvHD at 3 years was similar (HDCT: 52 vs RICT: 58%, P ¼ 0.14), although the incidence of extensive chronic GvHD was higher in the RICT recipients (HDCT: 37 vs RICT: 49%, P ¼ 0.03).
The unadjusted 3-year DFS and OS in HDCT and RICT were 41 and 28% (P ¼ 0.06) and 44 and 36% (P ¼ 0.62), respectively. By multiple Cox regression analysis, advanced disease (DFS: HR 1.57, 95% CI 1.10-2.24, P ¼ 0.01; OS: HR 1.61, 95% CI 1.10-2.37, P ¼ 0.02) and patient age more than 50 years (OS: HR 1.67, 95% CI 1.11-2.52, P ¼ 0.01) were associated with worse outcomes. After controlling for all other factors, intensity of conditioning (HDCT vs RICT) was not associated with DFS (HR 0.96, 95% CI 0.63-1.47, P ¼ 0.85) and OS (HR 1.32, 95% CI 0.85-2.06, P ¼ 0.22) ( Table 5 ). The same trends for DFS and OS were seen when we included the PS in the Cox model (DFS: HR 0.94, 95% CI 0.62-1.45, P ¼ 0.79; OS: HR 1.30, 95% CI 0.83-2.03, P ¼ 0.26), suggesting that type of transplant is not independently associated with survival.
Discussion
We compared total costs of RICT vs HDCT in a large observational cohort of 275 patients accrued over 3 years at Table 2 Univariate analyses for costs, days of hospitalization and the number of outpatient clinic visits Abbreviations: HDCT ¼ hematopoietic cell transplantation (HCT) with high-dose regimens; RICT ¼ HCT with reduced intensity regimens. 21, 22 While it may seem intuitive that discharging patients from the hospital earlier (as we do for RICT, typically on day þ 1) results in lower costs and hospitalization days overall, this strategy will only work if modifications to the conditioning regimen intensity that allow primarily outpatient transplantation do not also lead to increased relapse rates or other late complications that increase costs and need for hospitalization in later time periods. Although the results did not achieve statistical significance, the cumulative incidence of chronic GvHD was higher and unadjusted DFS was worse in the RICT group. These findings may explain the fact that the percentage of costs between 100 days and 1 year to total costs in the RICT group were higher than those in the HDCT group; however, such costs did not offset the lower initial hospitalization costs, at least within the first year after HCT. Some protocol-driven supportive care measures, such as filgrastim, methotrexate and sirolimus use, may have contributed to differences in time to engraftment and incidence of acute GvHD and thus influenced costs. However, an independent effect of RICT on costs was detected after adjusting for difference in time to engraftment and incidence of acute GvHD between the two groups. Our findings contrast with a small study of 23 patients, where rates of relapse, complications and OS differed, but no difference in costs between the two groups was observed. 38 Several limitations of our study should be explained. First, this is a single-institution observational study with a median follow-up of 3 years for survivors. Patients undergoing RICT procedures were older and more likely to have prior autologous or allogeneic HDCT, while patients undergoing HDCT procedures were more likely to have BM grafts. Multivariable adjustment and use of PSs may not fully account for baseline population differences. However, results of the subgroup analysis of patients over 50 years were consistent with the overall population.
Second, we excluded costs of clinic visits and rehospitalizations outside of the DFCI/BWH, because we did not have access to other systems' financial data. However, complete review of the medical records of all patients confirmed that the external clinic visits and rehospitalizations were seen equally in both groups and appeared to be a negligible fraction of expensive healthcare utilization (o4%), suggesting that our cost analysis was robust. 39 Third, some of the cost differences may be driven by difference in practice standards in each group. Indeed, the number of outpatient clinic visits at our institution and, thus, the median interval period between regular clinic visits in each group was different, which translates into a higher proportion of total outpatient costs in the RICT group (HDCT: 11%, RICT: 28%). On the other hand, outpatient costs for a clinic visit that were calculated by dividing total outpatient costs by the total number of clinic visits were very low compared with inpatient costs and similar between the two groups (HDCT: $1183 RICT: $1313, P ¼ 0.26). We did not measure costs for outpatient prescriptions in either group, but these are anticipated to be similar in both groups except for the first 3 weeks immediately after graft infusion, when RICT patients are primarily outpatient and HDCT patients are primarily inpatient. Finally, various kinds of RICTconditioning regimens used in clinical practice have their own profile of complications and clinical outcomes. Our results may only apply to RICT with fludarabine-(total dose 120 mg/m 2 ) and busulfan-(total dose 3.2 mg/kg) based conditioning.
Currently, RICT approaches are reserved for patients considered ineligible for HDCT procedures, whether due to older age, comorbidity or documented poor results with HDCT. This triage system presupposes that HDCT is the superior approach when a patient is felt to be able to tolerate a high-dose conditioning regimen and probably also reflects the more recent history of RICT as an 'experimental procedure'. However, we observed significantly lower costs and fewer days of hospitalization within the first year after transplantation in the RICT group even after adjustment for clinical characteristics in the population. This finding, coupled with similar success in clinical outcomes between HDCT and RICT, suggests that it may be reasonable to conduct a randomized trial in patients Abbreviations: CI ¼ confidence interval; HDCT ¼ hematopoietic cell transplantation (HCT) with high-dose regimens; HR ¼ hazard ratio; RICT ¼ HCT with reduced intensity regimens. a The variables included in the multiple Cox regression analyses were intensity of conditioning (HDCT vs RICT), patient age (more than 50 years vs less than or equal 50 years), donor age (more than 50 years vs less than or equal 50 years), patient-donor sex matching (female donor and male patient vs all other combinations), patient-donor relationship (unrelated vs related), patient-donor CMV serological status (CMV positive serology in either donor or patient vs CMV negative serology both in patient and donor), disease status (advanced vs less advanced) and graft source (PB vs BM). The values of intensity of conditioning and significant or marginal variables are shown. Reference groups: RICT, related, less advanced, other than female donor and male patient, less than or equal 50 years, BM, CMV negative serology both in patient and donor.
eligible for HDCT to address the question of whether RICT should actually be the default procedure, with HDCT reserved for patients requiring anticancer as well as immunosuppressive conditioning. While observational studies, such as ours, have inherent limitations, they are the best data available until a randomized trial can be conducted. We suggest that secondary endpoints, such as costs and quality of life considerations, may provide additional information about the relative merits of the two different approaches and are especially important if equivalent survival can be achieved.
